Cargando…
Targeted drug combination therapy design based on driver genes
Targeted therapies against cancer types with more than one driver gene hold bright but elusive promise, since approved drugs are not available for all driver mutations and monotherapies often result in resistance. Targeting multiple driver genes in different pathways at the same time may provide an...
Autores principales: | Zsákai, Lilian, Sipos, Anna, Dobos, Judit, Erős, Dániel, Szántai-Kis, Csaba, Bánhegyi, Péter, Pató, János, Őrfi, László, Matula, Zsolt, Mikala, Gábor, Kéri, György, Peták, István, Vályi-Nagy, István |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731102/ https://www.ncbi.nlm.nih.gov/pubmed/31523388 http://dx.doi.org/10.18632/oncotarget.26985 |
Ejemplares similares
-
The Effect of Belantamab Mafodotin on Primary Myeloma–Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells
por: Matula, Zsolt, et al.
Publicado: (2023) -
Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers
por: Brauswetter, Diána, et al.
Publicado: (2017) -
Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells
por: Matula, Zsolt, et al.
Publicado: (2021) -
Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes–A feasibility study
por: Marx, Anita, et al.
Publicado: (2023) -
Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia
por: Kövy, Petra, et al.
Publicado: (2021)